In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...

Bonus Sep 11, 2018 Sep 13, 2018 Jul 24, 2018 Bonus Ratio: 1 share(s) for every 1 shares held Bonus Jan 02, 1995 Jan 24, 1995 Sep 28, 1995 Bonus Ratio: 1 share(s) for every 1 shares held Rights May 21, ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...

The UK based drug firm GSK has agreed to pay up to $2.2bn (£1.7bn; €2bn) to settle claims that the heartburn drug ranitidine (previously marketed in the US as Zantac) caused cancer. The deal, ...

GSK paid $22.4 million on Sept. 27 for 2.8 million more shares of Wave Life Sciences for $8 each. GSK now owns 16.8 million ...

TD Cowen analyst Yaron Werber has maintained their neutral stance on GMAB stock, giving a Hold rating yesterday. Yaron Werber’s rating ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the ...

Daryl Brown, who was prescribed the antidepressant Seroxat in childhood because of his Tourette’s syndrome and OCD, tells ...

After hours: October 10 at 7:56 PM EDT Loading Chart for GSK ...

Biohaven has surged driven by promising data from its troriluzole trials for spinocerebellar ataxia and ongoing OCD studies.

The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD ...